Company Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Country | Belgium |
| Founded | 1999 |
| IPO Date | May 6, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,123 |
| CEO | Dr. Paulus A. Stoffels M.D., Ph.D. |
Contact Details
Address: Gen De Wittelaan L11 A3 2800 Mechelen, C9 00000 Belgium | |
| Phone | 3215342900 |
| Website | glpg.com |
Stock Details
| Ticker Symbol | GLPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001421876 |
| CUSIP Number | 36315X101 |
| ISIN Number | US36315X1019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paulus A. Stoffels M.D., Ph.D. | Chief Executive Officer, Chairman, Interim Head of Research & Development |
| Thad Huston | Executive Vice President, Chief Financial Officer and Chief Operating Officer |
| Sofie Van Gijsel | Head of Investor Relations |
| Valeria Cnossen | Executive Vice President and General Counsel |
| Marieke Vermeersch | Head of Corporate Communication |
| Annelies Missotten | Executive Vice President and Chief Human Resources Officer |
| Ellen Van Der Aar | Head of Development |
| Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior Vice President and Head of Business Development |
| Dirk De Naeyer | Head of Development Operations |
| Alice Dietrich | Head of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 16, 2024 | 6-K | Report of foreign issuer |
| May 16, 2024 | 6-K | Report of foreign issuer |
| May 3, 2024 | 6-K | Report of foreign issuer |
| May 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 1, 2024 | 6-K | Report of foreign issuer |
| May 1, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Mar 29, 2024 | 6-K | Report of foreign issuer |